PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19608720-8 2009 Lung lavage IL-4, IL-13, and tumor necrosis factor-alpha levels were all reduced by treatment with simvastatin (P < 0.05). Simvastatin 99-110 interleukin 13 Mus musculus 18-56 35450036-4 2022 This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells. Simvastatin 91-102 interleukin 13 Mus musculus 119-124 35450036-4 2022 This study proposes a novel combination therapy consisting of sequential administration of simvastatin incorporated in IL-13-functionalized long-circulating liposomes (IL-13-LCL-SIM) and doxorubicin encapsulated into PEG-coated extracellular vesicles (PEG-EV-DOX) to selectively target both tumor-associated macrophages and melanoma cells. Simvastatin 91-102 interleukin 13 Mus musculus 168-173 29914792-8 2019 However, IL-13 and TGF-beta levels were significantly decreased by BMSCs and BMSC + simvastatin combination therapy (P < 0.05 for all cases). Simvastatin 84-95 interleukin 13 Mus musculus 9-14 29914792-9 2019 The effect of simvastatin and BMSCs combination therapy on serum specific IgE levels as well as lung IL-13 and TGF-beta levels were significantly higher than the effect of BMSCs and simvastatin alone (P < 0.001 for IL-13 and P < 0.01 for other cases). Simvastatin 14-25 interleukin 13 Mus musculus 218-223 29914792-10 2019 CONCLUSIONS: Simvastatin and BMSCs combination therapy affects serum IgE as well as lung IL-13 and TGFbeta levels more than BMSC therapy and simvastatin therapy alone which may be due to increased BMSCs migration into the lung tissue. Simvastatin 13-24 interleukin 13 Mus musculus 89-94 27782356-10 2017 Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. Simvastatin 0-11 interleukin 13 Mus musculus 117-122 25213768-6 2014 The administration of simvastatin decreased the airway responsiveness, the number of airway inflammatory cells, and the interleukin (IL)-4, IL-5 and IL-13 concentrations in BAL fluid compared with vehicle-treated mice (P<0.05). Simvastatin 22-33 interleukin 13 Mus musculus 149-154 22939729-7 2012 Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF. Simvastatin 0-11 interleukin 13 Mus musculus 164-169 22583375-0 2012 Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells. Simvastatin 24-35 interleukin 13 Mus musculus 39-44 22583375-4 2012 OBJECTIVES: In this study, we evaluated whether simvastatin inhibits IL-13-induced pro-inflammatory gene expression of asthma-related cytokines in well-differentiated primary mouse tracheal epithelial (MTE) cell cultures. Simvastatin 48-59 interleukin 13 Mus musculus 69-74 22583375-5 2012 We hypothesized that simvastatin reduces the expression of IL-13-inducible genes in MTE cells. Simvastatin 21-32 interleukin 13 Mus musculus 59-64 22583375-7 2012 RESULTS: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1; MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3alpha)) in MTE cells. Simvastatin 23-34 interleukin 13 Mus musculus 63-68 22583375-9 2012 CONCLUSIONS: Simvastatin modulates the gene expression of selected IL-13-inducible pro-inflammatory cytokines and chemokines in primary mouse tracheal epithelial cells. Simvastatin 13-24 interleukin 13 Mus musculus 67-72